Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14696790 | 0.86 | KDM4E (0.47) | LMNAKDM4EKMT2AALDH1A1MAPT | |
| SCHEMBL868452 | 0.86 | LMNA (0.44) | LMNAKDM4ECSNK2A1KMT2AMEN1 | |
| SCHEMBL10102699 | 0.86 | LMNA (0.44) | LMNAKDM4ECSNK2A1KMT2AMEN1 | |
| SCHEMBL28794242 | 0.83 | LMNA (0.43) | LMNAKDM4ECSNK2A1KMT2AMEN1 | |
| SCHEMBL10102709 | 0.79 | LMNA (0.49) | LMNAKDM4ECSNK2A1KMT2AMEN1 | |
| SCHEMBL14713556 | 0.77 | KDM4E (0.43) | LMNAKDM4EKMT2AALDH1A1MAPT | |
| SCHEMBL28794244 | 0.75 | LMNA (0.46) | LMNAKDM4ECSNK2A1KMT2AALDH1A1 | |
| SCHEMBL10108425 | 0.74 | CSNK2A1 (0.40) | LMNAKDM4ECSNK2A1KMT2AMEN1 | |
| SCHEMBL10102691 | 0.73 | KDM4E (0.61) | LMNAKDM4EKMT2AALDH1A1MAPT | |
| SCHEMBL31144984 | 0.73 | KDM4E (0.51) | LMNAKDM4ECSNK2A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | LMNA 1423/4885KDM4E 724/4885CSNK2A1 323/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | LMNA 1877/4885KDM4E 667/4885CSNK2A1 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.